Koninklijke Philips N.V. NY Reg (PHG) Stock Price & How to Invest
Last updated July 2026
Short answer
PHG is the NYSE-listed ADR of Koninklijke Philips N.V., the Dutch health-technology company that makes medical imaging systems, patient monitoring, and personal-health devices. It is a large, legitimate operating business that has been working through a multi-year turnaround, so investors typically treat it as a recovery and dividend story in medical devices rather than a fast grower.
PHG stock price
As of 2026-07-17, Koninklijke Philips N.V. NY Reg (PHG) last closed at $26.95, up 9.6% over the past year. Over the past 52 weeks it has traded between $24.54 and $32.91.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Koninklijke Philips N.V. NY Reg's investor relations page. Walnut is informational, not investment advice.
What does Koninklijke Philips N.V. NY Reg (PHG) do?
Koninklijke Philips N.V. (Royal Philips) is a Netherlands-based health-technology company that generated roughly EUR 17.8 billion (about $19 billion) in 2025 sales across three segments: Diagnosis and Treatment (imaging systems, image-guided therapy, ultrasound), Connected Care (patient monitoring, hospital informatics, and its Respironics sleep and respiratory business), and Personal Health (electric shavers, toothbrushes, and mother-and-child care). US investors most commonly access it through the PHG American Depositary Receipt on the NYSE, which represents ordinary shares that also trade in Amsterdam; the ADR structure means currency moves between the euro and the dollar affect the quoted price and the dividend.
The investment picture is a turnaround. After exiting its lighting and appliance roots to become a pure health-technology company, Philips spent recent years absorbing the 2021 Respironics device recall, related US litigation, and softness in China. In 2025 it returned to a reported net income of about EUR 897 million and lifted its adjusted EBITA margin to 12.3 percent, and it entered 2026 reiterating guidance for 3 to 4.5 percent comparable sales growth and a 12.5 to 13.0 percent adjusted EBITA margin. The story now hinges on whether order intake and margin gains can compound while the China market and legacy risks normalize.
What's driving Koninklijke Philips N.V. NY Reg (PHG)?
1. Margin recovery and cost discipline
Philips lifted its adjusted EBITA margin to 12.3 percent in 2025 and guides to 12.5 to 13.0 percent for 2026, driven by productivity savings, an innovation-led gross margin, and a leaner cost base. Continued margin expansion is the clearest lever for earnings growth given only modest top-line growth. Progress here is what the turnaround thesis largely rests on.
2. Order intake and installed-base momentum
Comparable order intake grew 6 percent in Q1 2026, which supports future revenue in the capital-equipment-heavy Diagnosis and Treatment segment. Hospitals buying imaging systems then generate recurring service, software, and consumables revenue over the equipment life. Sustained order growth would signal that customers are returning after the recall-era disruption.
3. Diversified health-technology portfolio
The mix of hospital systems (imaging, monitoring), the Respironics respiratory franchise, and consumer Personal Health products (shavers, toothbrushes) gives Philips exposure to both capital cycles and steadier consumer demand. Personal Health grew about 8 percent in 2025, offsetting flat Diagnosis and Treatment. This breadth can smooth results across differing end-market cycles.
4. Cash generation and dividend
Philips produced roughly EUR 512 million of free cash flow in 2025 and proposed a dividend of EUR 0.85 per share, supporting a forward yield in the mid-single-digit-percent range on the ADR. Rebuilding cash flow toward its EUR 1.3 to 1.5 billion 2026 target would give the company more room to invest and return capital. The dividend is a meaningful part of the total-return case.
What are the risks to Koninklijke Philips N.V. NY Reg (PHG)?
China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. The 2021 Respironics recall led to large US litigation; a roughly $1.1 billion personal-injury settlement and a medical-monitoring class-action resolution have reduced but not fully eliminated legal and reputational overhang. Tariffs and cost inflation pressure margins and partly offset productivity gains. As an ADR of a euro-reporting company, US investors bear currency risk between the euro and the dollar on both price and dividends. Competition from larger and well-capitalized rivals in imaging can pressure pricing and market share.
How is Koninklijke Philips N.V. NY Reg (PHG) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Koninklijke Philips N.V. NY Reg's investor relations page or your broker.
- Revenue (2025): ~EUR 17.8B (~$19B)
- Net income (2025): ~EUR 897M
- Adjusted EBITA margin (2025): ~12.3%
- Market cap: ~$27B
- P/E (TTM): ~24x (forward ~16x)
- Forward dividend yield: ~3.7%
Philips trades at a trailing P/E in the low-20s that compresses to the mid-teens on a forward basis, reflecting expectations that margin recovery lifts earnings. The stock carried a market cap around $27 billion in mid-2026 on roughly $19 billion of sales, a price-to-sales near 1.3x. Figures are approximate, reported in euros, and converted to dollars at prevailing rates for the ADR.
Who competes with Koninklijke Philips N.V. NY Reg (PHG)?
Large medical-imaging and diagnostics rivals
Siemens Healthineers and GE HealthCare are Philips' core competitors in imaging (MRI, CT, X-ray) and diagnostics, with Canon Medical Systems also in the mix. These players compete on R&D scale, bundled pricing, and installed-base reach, and often lead in specific modalities.
Patient monitoring and hospital informatics
In Connected Care, Philips competes with GE HealthCare, Medtronic, and Baxter (Hillrom) in patient monitoring and clinical informatics, where software, data integration, and service contracts increasingly differentiate vendors.
Consumer personal-health brands
In Personal Health, Philips (shavers, Sonicare toothbrushes, mother-and-child care) competes with Procter and Gamble (Braun, Oral-B), Panasonic, and other consumer-electronics and grooming brands on brand strength, price, and retail distribution.
How to invest in Koninklijke Philips N.V. NY Reg (PHG)
There are three common ways to get PHG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PHG sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PHG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Koninklijke Philips N.V. NY Reg (PHG)
PHG is a way to own a recovering European medical-device leader through a US-listed ADR, with the investment case resting on margin repair, order growth, and how quickly China and past litigation overhangs fade.
More on Koninklijke Philips N.V. NY Reg (PHG)
Whether PHG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PHG a buy?, and where the stock could go from here in the PHG stock forecast.
For income investors, whether PHG pays a dividend and how the payout looks is covered in does PHG pay a dividend?
Build a basket around PHG with Walnut
Use Koninklijke Philips N.V. NY Reg as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is PHG?
+
PHG is the NYSE-listed American Depositary Receipt (ADR) of Koninklijke Philips N.V., known as Royal Philips, a Dutch health-technology company. Each ADR represents ordinary shares that also trade in Amsterdam. Philips makes medical imaging, patient monitoring, and personal-health products.
Is PHG an American company?
+
No. Philips is headquartered in Amsterdam, the Netherlands, and reports in euros. US investors buy exposure through the PHG ADR on the NYSE, which tracks the euro-denominated shares, so currency moves between the euro and the dollar affect the ADR price and dividends.
What does Philips actually do now?
+
Philips is a pure health-technology company after exiting lighting and consumer appliances. It operates in three segments: Diagnosis and Treatment (imaging and image-guided therapy), Connected Care (patient monitoring and the Respironics respiratory business), and Personal Health (shavers, toothbrushes, and mother-and-child care).
How did Philips perform in 2025?
+
Philips reported roughly EUR 17.8 billion in 2025 sales with about 2 percent comparable growth, returned to a net income of about EUR 897 million, and raised its adjusted EBITA margin to 12.3 percent. It proposed a dividend of EUR 0.85 per share and generated about EUR 512 million of free cash flow.
What was the Respironics recall?
+
In 2021 Philips recalled certain Respironics CPAP, Bi-Level PAP, and ventilator devices over foam degradation concerns, triggering extensive US litigation. Philips reached a roughly $1.1 billion personal-injury settlement and resolved a medical-monitoring class action, which reduced but did not entirely remove the legal and reputational overhang.
Does PHG pay a dividend?
+
Yes. Philips proposed a 2025 dividend of EUR 0.85 per share, which translates to a forward yield in the mid-single-digit-percent range (around 3.7 percent) on the ADR. Because the dividend is paid in euros, the dollar amount ADR holders receive varies with the exchange rate and any withholding tax.
Who are Philips' main competitors?
+
In medical imaging and diagnostics its main rivals are Siemens Healthineers, GE HealthCare, and Canon Medical. In patient monitoring it competes with GE HealthCare, Medtronic, and Baxter, and in consumer personal-health products it faces Procter and Gamble (Braun, Oral-B) and Panasonic.
What are the biggest risks for PHG?
+
Key risks include continued weakness and share loss in China, residual litigation and reputational effects from the Respironics recall, tariff and cost-inflation pressure on margins, and euro-to-dollar currency risk on the ADR. Competition from larger imaging rivals can also pressure pricing and market share.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Koninklijke Philips N.V. NY Reg's investor relations page or your broker before making investment decisions.